Jean Bertoldo

Super happy, it is both a privilege and a great responsability, but oh boy! the satisfaction, the excitment is beyond words. Check out, my group is finally here. #newPI ccia.org.au/about-the-inst…

The team is growing. Welcome Montana and Elliot. 🤜🏻🤛🏻👨🏽‍🔬👨🏼‍🔬👩🏼‍🔬👩🏽‍🔬👨🏻‍🔬🧑🏽‍🔬 @KidsCancerInst @chadtough

What an amazing event. Thank you @chadtough for such an incredible experience and for funding our work @KidsCancerInst. Together in the fight against DIPG.

Really happy to be in my first @chadtough Research Workshop. Looking foward to meet the community, and establish new collaborations.

The team is ready to go. Touring our new home in the almost finished MCCCC. Let's roll.

1/ Delighted to share the published version of this work from brilliant #CancerNeuroscience post-doc @TaraBarronPhD detailing GABAergic neuron-to-glioma synapses in #DIPG/#DMG. 🧵 Open access link: #Sec2" target="_blank" rel="nofollow noopener">nature.com/articles/s4158…

The CBDD lab at #CCIResSymp @KidsCancerInst. And no, we didn't coordinate the dress code🤣🤣. Congrats to Josh on his oustanding talk on how we are using unnorthodox methods to target DMGs

@charles_debock @NatureComms @KidsCancerInst Fantastic work @charles_debock! Congrats to the team!!👏🏻👏🏻👏🏻

Following our publication on T-ALL this week, pleased to share another paper from our group now published in @NatureComms linking PU.1 to glucocorticoid sensitivity in B-ALL rdcu.be/dZB01 which was a massive team effort @KidsCancerInst ; 🧵n/8 below

Today we welcome @DonaAnnJOHNS1 who joins my lab at @KidsCancerInst as our new Research Officer. Dona expertise in paediatric oncology and epigenetics is timely in our efforts to develop a targeted therapy for DIPG.

Fantastic achievement and well deserved. Congrats🙏🏻

Looking for a medicinal chemist and a research assistant to join my lab at @KidsCancerInst. Please DM me if you are interested in cancer drug discovery and paediatric CNS tumours.

Super happy. News on our research in #DIPG @KidsCancerInst and recent funding from @chadtough in my native language. 😊

A bold research project at @KidsCancerInst that could lead to the first-ever effective drug to treat deadly brain cancer, #DIPG, received a major boost this month, with a $US400,000 grant awarded to @Jean_Bertoldo by the US-based charity, @ChadTough. ccia.support/JBGrant

@Hakanzt50881607 chimerix.com/our-pipeline/i…

@jean_bertoldo @TheASMR1 @KidsCancerInst My nephew ...Aktürk, who was diagnosed with H3K27M-mutant glioma, has limited treatment options. Can you help us find a solution or alternative trial? Any help would mean the world to us. Thanks for considering, Hakan Öztürk email.hakanozturk@gmail.com

Happy to present a lightning session on our work on targeting and modulating H3K27M activity in DIPG at #ASMRNSWASM2024 @TheASMR1 @KidsCancerInst

We are recruiting! A Research Officer position to work on our recently funded @chadtough grant @KidsCancerInst. Interested in cancer drug discovery and paediatric brain cancer? Please follow the links. linkedin.com/jobs/view/3967… Research Officer (connxcareers.com)

NEW INVESTIGATOR GRANT: Dr. Jean Bertoldo, Children’s Cancer Institute (Co-funded by the Violet Foundation)

Super happy and grateful to @chadtough for funding our work on developing H3K27M-targeting chemical probes. Attacking the Achilles' heel of DIPG might be the crucial step toward eradicating this incurable cancer. @KidsCancerInst #NewInvestigatorGrant

@EmmyFleuren @TheASMR1 @KidsCancerInst Thank you Emmy. Congratulations to you too. Well deserved award.😁

@jean_bertoldo @TheASMR1 @KidsCancerInst You did great!! @jean_bertoldo @TheASMR1 @KidsCancerInst

Chromatin-targeted drug discovery at “a very special moment” bit.ly/4ciYrph Cigall Kadoch, a researcher at Dana-Farber Cancer Institute & co-founder of Foghorn Therapeutics, discusses the case for a new wave of epigenetic drugs targeting chromatin remodelling complexes

@ProfDavidZieg Amazing achievement @ProfDavidZieg. Congrats to you and the amazing ZERO Team. This is fantastic results and a hope for all children and families suffering from this devastating disease. Proud to be at @KidsCancerInst. One more milestone towards the cure.

Excited to share our Nature Medicine paper on the clinical benefit of precision medicine for children with high risk cancers. We report on the first 384 patients whom we followed for 3 years. Significantly improved outcomes with precision guided therapies. rdcu.be/dJ6yK